TCV-309 is an inhibitor of platelet activating factor (PAF). TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. TCV-309 attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats. TCV-309 inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.

131311-25-6

C30H34BrN5O7

656.52

TCV309

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years